ASX:OSL

OncoSil Medical Competitors

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume2.17 million shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

OncoSil Medical (ASX:OSL) Vs. BUX, IME, BD1, CRL, CTE, and DVL

Should you be buying OSL stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to OncoSil Medical, including (BUX) (BUX), 12144 (IME), BARD1 Life Sciences (BD1), Charles River Laboratories International (CRL), Cryosite (CTE), and dorsaVi (DVL).

OncoSil Medical vs. (BUX) Stock

OncoSil Medical (ASX:OSL) and (BUX) (CNSX:BUX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares OncoSil Medical and (BUX)'s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OncoSil Medical	$2.22 million	0.00	$-5,651,400.83	A($0.01)	N/A
(BUX)	N/A	N/A	N/A	N/A	N/A

(BUX) has lower revenue, but higher earnings than OncoSil Medical.

Profitability

This table compares OncoSil Medical and (BUX)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OncoSil Medical	N/A	N/A	N/A
(BUX)	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for OncoSil Medical and (BUX), as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OncoSil Medical	0	0	0	0	N/A
(BUX)	0	0	0	0	N/A

Summary

OncoSil Medical beats (BUX) on 1 of the 1 factors compared between the two stocks.

OncoSil Medical vs. 12144 Stock

OncoSil Medical (ASX:OSL) and 12144 (CNSX:IME) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for OncoSil Medical and 12144, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OncoSil Medical	0	0	0	0	N/A
12144	0	0	0	0	N/A

Valuation & Earnings

This table compares OncoSil Medical and 12144's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OncoSil Medical	$2.22 million	0.00	C$-5,651,400.83	A($0.01)	N/A
12144	N/A	N/A	N/A	N/A	N/A

12144 has lower revenue, but higher earnings than OncoSil Medical.

Profitability

This table compares OncoSil Medical and 12144's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OncoSil Medical	N/A	N/A	N/A
12144	N/A	N/A	N/A

Summary

OncoSil Medical beats 12144 on 1 of the 1 factors compared between the two stocks.

OncoSil Medical vs. BARD1 Life Sciences Stock

OncoSil Medical (ASX:OSL) and BARD1 Life Sciences (ASX:BD1) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Earnings and Valuation

This table compares OncoSil Medical and BARD1 Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OncoSil Medical	$2.22 million	0.00	$-5,651,400.83	A($0.01)	N/A
BARD1 Life Sciences	$612,251.00	0.00	$-6,644,706.43	A($0.08)	N/A

OncoSil Medical has higher revenue and earnings than BARD1 Life Sciences.

Profitability

This table compares OncoSil Medical and BARD1 Life Sciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OncoSil Medical	N/A	N/A	N/A
BARD1 Life Sciences	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for OncoSil Medical and BARD1 Life Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OncoSil Medical	0	0	0	0	N/A
BARD1 Life Sciences	0	0	0	0	N/A

Summary

OncoSil Medical beats BARD1 Life Sciences on 3 of the 3 factors compared between the two stocks.

OncoSil Medical vs. Charles River Laboratories International Stock

OncoSil Medical (ASX:OSL) and Charles River Laboratories International (CNSX:CRL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares OncoSil Medical and Charles River Laboratories International's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OncoSil Medical	N/A	N/A	N/A
Charles River Laboratories International	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings for OncoSil Medical and Charles River Laboratories International, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OncoSil Medical	0	0	0	0	N/A
Charles River Laboratories International	0	0	0	0	N/A

Valuation & Earnings

This table compares OncoSil Medical and Charles River Laboratories International's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OncoSil Medical	$2.22 million	0.00	$-5,651,400.83	A($0.01)	N/A
Charles River Laboratories International	N/A	N/A	N/A	N/A	N/A

Charles River Laboratories International has lower revenue, but higher earnings than OncoSil Medical.

Summary

OncoSil Medical beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

OncoSil Medical vs. Cryosite Stock

OncoSil Medical (ASX:OSL) and Cryosite (ASX:CTE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares OncoSil Medical and Cryosite's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OncoSil Medical	N/A	N/A	N/A
Cryosite	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings for OncoSil Medical and Cryosite, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OncoSil Medical	0	0	0	0	N/A
Cryosite	0	0	0	0	N/A

Valuation & Earnings

This table compares OncoSil Medical and Cryosite's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OncoSil Medical	$2.22 million	0.00	$-5,651,400.83	A($0.01)	N/A
Cryosite	$9.71 million	0.00	$515,455.60	A$0.01	N/A

Cryosite has higher revenue and earnings than OncoSil Medical.

Summary

Cryosite beats OncoSil Medical on 3 of the 3 factors compared between the two stocks.

OncoSil Medical vs. dorsaVi Stock

dorsaVi (ASX:DVL) and OncoSil Medical (ASX:OSL) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Profitability

This table compares dorsaVi and OncoSil Medical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
dorsaVi	N/A	N/A	N/A
OncoSil Medical	N/A	N/A	N/A

Earnings & Valuation

This table compares dorsaVi and OncoSil Medical's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
dorsaVi	$1.65 million	0.00	$-3,158,396.93	A($0.01)	N/A
OncoSil Medical	$2.22 million	0.00	$-5,651,400.83	A($0.01)	N/A

dorsaVi has higher earnings, but lower revenue than OncoSil Medical.

Analyst Recommendations

This is a breakdown of recent ratings for dorsaVi and OncoSil Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
dorsaVi	0	0	0	0	N/A
OncoSil Medical	0	0	0	0	N/A

Summary

OncoSil Medical beats dorsaVi on 2 of the 3 factors compared between the two stocks.